文献速递核素与放射性配体治疗肿瘤 PET/CT

高危转移性去势抵抗性前列腺癌患者接受177Lu-PSMA-617放射性配体治疗中联合225Ac-PSMA-617增量的前瞻性注册研究初步经验

225 Ac-PSMA-617 Augmentation in High-Risk mCRPC Undergoing 177 Lu-PSMA-617 Radioligand Therapy : Pilot Experience From a Prospective Registry.
PubMed 文献 · Clin Nucl Med · 2024-05-21

该初步研究基于前瞻性注册研究(NCT04833517),纳入33例高危转移性去势抵抗性前列腺癌患者,在177Lu-PSMA-617放射性配体治疗基础上联合1个或多个周期225Ac-PSMA-617增量治疗。2周期后血清PSA中位下降49.1%,16/33(48.5%)患者达部分缓解,中位PSA无进展生存期7.2个月,中位总生存期14.8个月;碱性磷酸酶、乳酸脱氢酶、Eastern European Oncology Group体能状态评分及内脏转移与总生存期显著相关。多数不良事件为轻至中度,仅1例(3.0%)3级贫血。

要点

  • 33例高危mCRPC患者接受177Lu-PSMA-617联合225Ac-PSMA-617增量治疗,2周期后PSA中位下降49.1%。
  • 中位PSA无进展生存期7.2个月,中位总生存期14.8个月。
  • 碱性磷酸酶、乳酸脱氢酶、体能状态评分及内脏转移与总生存期显著相关。

核心结论

  • 在高危mCRPC患者中,177Lu-PSMA-617放射性配体治疗联合225Ac-PSMA-617增量似乎是有效且安全性良好的治疗选择。

研究设计与样本

  • 前瞻性注册研究(NCT04833517)的初步研究,纳入33例高危mCRPC患者,接受177Lu-PSMA-617放射性配体治疗并联合1个或多个周期225Ac-PSMA-617增量治疗。

主要发现

  • 2周期治疗后血清PSA中位下降49.1%,16/33(48.5%)患者达部分缓解。
  • 中位PSA无进展生存期7.2个月,中位总生存期14.8个月。
  • Kaplan-Meier分析(log-rank检验)显示碱性磷酸酶(P < 0.001)、乳酸脱氢酶(P = 0.035)、Eastern European Oncology Group体能状态评分(P = 0.037)及内脏转移(P = 0.029)与总生存期显著相关。
  • 多数记录的不良事件为轻至中度,高级别不良事件非常有限,仅1例(3.0%)3级贫血。
  • 治疗相关轻度口干记录于6/33(18.2%)患者。

关键数值与推荐

  • 疗效评估采用2周期治疗后血清PSA值。
  • 不良事件采用Common Terminology Criteria for Adverse Events评估。
  • 共测试12项潜在治疗前生物标志物与总生存期的关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This pilot study investigates the efficacy and safety profile as well as predictive biomarkers of 225 Ac-PSMA-617-augmented 177 Lu-PSMA-617 radioligand therapy (RLT) in a cohort of high-risk patients with metastatic castration-resistant prostate cancer (mCRPC), enrolled in a prospective registry (NCT04833517). PATIENTS AND METHODS: A group of n = 33 high-risk mCRPC patients received 177 Lu-PSMA-617 RLT, augmented by 1 or more cycles of 225 Ac-PSMA-617. Response was assessed by prostate-specific antigen (PSA) serum value after 2 cycles of treatment. Overall survival (OS) and PSA-based progression-free survival were evaluated using Kaplan-Meier analysis. To assess the side effect profile, Common Terminology Criteria for Adverse Events were applied. In total, 12 potential pretherapeutic biomarkers were tested for association with OS. RESULTS: The median decrease in serum PSA value was -49.1%, and 16/33 (48.5%) patients experienced a partial response after 2 cycles RLT. The median PSA-based progression-free survival and median OS was 7.2 and 14.8 months, respectively. Alkaline phosphatase ( P < 0.001), lactate dehydrogenase ( P = 0.035), Eastern European Oncology Group Performance Score ( P = 0.037), and the presence of visceral metastases ( P = 0.029) revealed significant association with OS in Kaplan-Meier analysis (log-rank test). Most of the recorded adverse events were rated as mild or moderate. Higher-grade adverse events were very limited with only 1 case (3.0%) of grade 3 anemia. Treatment-related mild xerostomia was recorded in 6/33 (18.2%) patients. CONCLUSIONS: 225 Ac-PSMA-617 augmentation in high-risk mCRPC undergoing 177 Lu-PSMA-617 RLT appears to be an effective treatment option with a favorable safety profile. The pretherapeutic values of alkaline phosphatase, lactate dehydrogenase, the Eastern European Oncology Group Performance Score, and the presence of visceral metastases may be appropriate biomarkers predicting survival outcome of this treatment regimen.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Rosar F, Burgard C, Rohloff LV, et al. 225 Ac-PSMA-617 Augmentation in High-Risk mCRPC Undergoing 177 Lu-PSMA-617 Radioligand Therapy : Pilot Experience From a Prospective Registry. Clin Nucl Med. 2024. PMID: 38769643. doi:10.1097/RLU.0000000000005253

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。